

Emricasan, a pan caspase inhibitor, improves survival and portal hypertension in a murine model of common bile-duct ligation


Akiko Eguchi¹, Yukinori Koyama², Alexander Wree¹, Casey Johnson¹, Ryota Nakamura¹, Patty Contreras³, Ariel E. Feldstein¹

¹Department of Pediatrics, University of California – San Diego, La Jolla, USA, ²School of Medicine, University of California – San Diego, La Jolla, USA, ³Conatus Pharmaceuticals Inc., San Diego, USA

PURPOSE / AIM

- ★ Development of portal hypertension (PTH) is a central prognostic factor in patients with cirrhosis. Current pharmacotherapy remains limited and novel therapies are greatly needed.
- ★ Circulating extracellular vesicles (EVs) are released by hepatocytes in a caspase dependent manner, are increased in circulation of patients with cirrhosis and contribute to PTH via induction of impaired vasoconstrictor responses
- ★ We tested the hypothesis that Emricasan (IDN-6556) a pan-caspase inhibitor ameliorates PTH via its anti-fibrotic effects and reduction in release of EVs.

METHODS



RESULTS




Figure 1. Liver/body ratio and survival curve: The liver/body ratio was significantly increased in BDL group compared to Control group ($p < 0.001$), but no difference between CBDL-Placebo group and CBDL-IDN-6556 group. Nearly all CBDL-IDN-6556 survived compared to CBDL-Placebo group ($p < 0.05$). [*** $p < 0.001$, * $p < 0.05$]




Figure 2. Portal pressure: Assessment of portal pressure showed a significant increase in CBDL-placebo treated mice compared to sham-operated mice ($p < 0.001$). In contrast, CBDL-IDN-6556 treated mice had significantly lower levels than CBDL-Placebo treated animals ($p < 0.05$). [*** $P < 0.001$, * $P < 0.05$]




Figure 3. Liver histology and ALT: Analysis of liver injury showed that CBDL-IDN-6556 treated mice had improved liver histology stained by H&E. Serum ALT levels showed an decreasing trend in CBDL-IDN-6556. [** $p < 0.01$, * $p < 0.05$]




Figure 4. Liver fibrosis: IDN-6556 treatment resulted in a decrease in fibrosis, but the changes did not reach statistical significance suggesting that the effects on PTH are at least in part independent of the anti-fibrotic effects of the drug. [*** $p < 0.001$, * $p < 0.05$]




Figure 5. Liver cell death; CBDL-IDN-6556 treated mice had reduced liver cell death assessed by TUNEL staining. [* $p < 0.05$]




Figure 6. Circulating EVs in blood via flow cytometry: Circulating EVs were quantified using calcein positive EVs (histogram). Circulating EVs were increased in CBDL and had two populations (exo: exosomes and MP: microparticles) (dot plot). IDN-6556 treatment resulted in a significant decrease in circulating MPs at Day 3 ($p < 0.05$) and at Day 10 ($p < 0.01$). [** $P < 0.01$, * $P < 0.05$]

CONCLUSIONS

These data demonstrate that in a murine model of long-term common bile-duct ligation, survival and PTH are improved by pan-caspase inhibitor therapy. Circulating MP may have function by involving the PTH reduction mechanism(s) through target cell activation, however further investigation is needed. Emricasan is a promising agent for the treatment of PTH.

DISCLOSURES /FUNDINGS

The work was funded by Conatus Pharmaceuticals.